Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial
第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Yunjiang,Zhang Xiangmei,Wang Li,et al.Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial[J].CANCER RESEARCH.2021,81(4):
APA：
Liu, Yunjiang,Zhang, Xiangmei,Wang, Li,Cao, Miao,Zhang, Shuo...&Wang, Jintian.(2021).Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial.CANCER RESEARCH,81,(4)
MLA：
Liu, Yunjiang,et al."Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial".CANCER RESEARCH 81..4(2021)
医学